Latest Research Reports

US faces high, growing burden of CDI

US faces high, growing burden of CDI

Despite challenges, pain-related indications are most frequently researched clinical trials

Despite challenges, pain-related indications are most frequently researched clinical trials

Will Orencia be able to compete in an already crowded market?

Will Orencia be able to compete in an already crowded market?

Chlamydia testing, one step back but two steps forward

Chlamydia testing, one step back but two steps forward

Non-industry trials were more frequent than industry trials in 2016

Non-industry trials were more frequent than industry trials in 2016

Which class of drugs is set to have the biggest impact on the cancer market?

Which class of drugs is set to have the biggest impact on the cancer market?

Monoclonal antibodies make up seven out of the top ten investigated drugs in 2016

Monoclonal antibodies make up seven out of the top ten investigated drugs in 2016

Novartis, Pfizer, Amgen, and Merck: key players in the autoimmune biosimilars space

Novartis, Pfizer, Amgen, and Merck: key players in the autoimmune biosimilars space

EMA set to approve plethora of oncology drugs

EMA set to approve plethora of oncology drugs

Top indications and therapy areas for 2012-2016 clinical trials in Israel

Top indications and therapy areas for 2012-2016 clinical trials in Israel

Orphan cancer drugs take up 37% of market share

Orphan cancer drugs take up 37% of market share

US and UK stand out with higher disease prevalence of two autoimmune diseases

US and UK stand out with higher disease prevalence of two autoimmune diseases

Is diagnosed non-invasive ductal carcinoma in-situ breast cancer rarer in China?

Is diagnosed non-invasive ductal carcinoma in-situ breast cancer rarer in China?

Anticipated approval timeline of PARP inhibitors in HER2-negative breast cancer

Anticipated approval timeline of PARP inhibitors in HER2-negative breast cancer

A look at atrial fibrillation’s market size forecast

A look at atrial fibrillation’s market size forecast

Industry-sponsored clinical trials initiated in Q1 2017

Industry-sponsored clinical trials initiated in Q1 2017

China shows leading emerging market growth in R&D spend

While the global pharmaceutical markets have typically been dominated by US, Europe and Japan, emerging markets have been steadily increasing their prominence in the global space over the...

China shows leading emerging market growth in R&D spend

Innovative new drugs could produce a watershed moment for dermatology sufferers

Innovative new drugs could produce a watershed moment for dermatology sufferers

Pharma licensing deals 2016/2017 comparison

Pharma licensing deals 2016/2017 comparison

Brazil: 2016 clinical trials activity at lowest point in five years

Brazil: 2016 clinical trials activity at lowest point in five years

Eylea enables Regeneron to dominate the ocular market

Eylea enables Regeneron to dominate the ocular market